Datta Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 13-12-2024
- Paid Up Capital ₹ 1.50 M
as on 13-12-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2021
About Datta Bio Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Aruna Kommuri, Prashanth Kommuri, Rakesh Kommuri, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24299TG2020PTC145446
- Company No.
145446
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Oct 2020
- Date of AGM
12 Jan 2022
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Datta Bio Pharma?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aruna Kommuri  | Director | 31-Oct-2020 | Current |
| Prashanth Kommuri | Director | 30-Oct-2020 | Current |
| Rakesh Kommuri | Director | 30-Oct-2020 | Current |
| Kommuri Divyasri | Director | 31-Oct-2020 | Current |
| Saipriyanka Kommuri | Director | 30-Oct-2020 | Current |
| Nagapriyanka Sanvally | Director | 31-Oct-2020 | Current |
Financial Performance of Datta Bio Pharma.
Enhance accessibility to Datta Bio Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Datta Bio Pharma?
Unlock access to Datta Bio Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sai Pragathi Estates And Constructions Private LimitedActive 27 years 3 monthsPrashanth Kommuri and Rakesh Kommuri are mutual person
Sowity Infra Private LimitedActive 7 years 3 daysPrashanth Kommuri and Rakesh Kommuri are mutual person
- Enliven Archive Publishing Private LimitedActive 10 years 10 months
Kommuri Divyasri is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Datta Bio Pharma?
Datta Bio Pharma has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Datta Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Datta Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
